The long-term goal is to develop a novel immune therapeutic approach to treating chronic HBV infection. There is currently no cure for the 350 million patients who are already chronically infected with hepatitis B virus (HBV). HBV replication can be effectively inhibited by anti-HBV drugs, but HBsAg is still expressed from HBV cccDNA or integrated genomes. The mechanisms of HBV-induced liver diseases, including chronic infection, immune responses, fibrosis/cirrhosis and liver cancer, are unclear due to a lack of relevant animal models. This project will take advantage of four key novel advancements in the PIs'groups: i) a novel humanized mouse model with human immune system &human liver (AFC8-hu HSC/Hep mice) that supports HBV infection, immune responses, hepatitis and fibrosis in the humanized liver;ii) human monoclonal antibodies (mAb) with high affinity to HBsAg that can neutralize HBV and clear extracellular HBs in vivo;iii) the newly developed AAV/HBV1.3 model in immune competent neonate and young adult mice;and iv) the LIGHT-based therapeutic vaccine approach that overcomes immune tolerance in the liver. We hypothesize that, by reducing HBV virions/HBsAg with antivirals and high affinity HBs mAb, the LIGHT-based HBV therapeutic vaccine will be effective to break HBV-induced immune tolerance, induce anti-HBV immunity and cure HBV infection. With complementary expertise, the two PIs will thus address the following specific questions related to HBV- induced immunopathology and immune therapeutics: (i) How does HBV infection modulate human T cell function in the liver and spleen/LN in vivo? (ii) What is the role of HBV persistence and PD1/TIM3 in impaired human immune responses in the liver? (iii) Will Ad-LIGHT-HBs vaccination (with HBs clearance mAb and antiviral) be able to cure an ongoing HBV infection? (iv) Is preS1 a better target than HBsAg to break tolerance to induce HBV neutralizing antibodies? Answers to these questions will have a significant impact on the field. The key findings will be confirmed in HBV-infected patients, and in future clinical trials.
This project proposes to develop a novel immune therapeutic approach to treating chronic hepatitis B virus (HBV) infection, using a novel humanized mouse model with both a human immune system and human liver cells. The findings will establish the foundation for future study and shed light on novel therapeutic strategies of chronic diseases.
|Bility, Moses T; Curtis, Anthony; Su, Lishan (2014) A chimeric mouse model to study immunopathogenesis of HCV infection. Methods Mol Biol 1213:379-88|
|Yang, Xuanming; Zhang, Xunmin; Sun, Yonglian et al. (2014) A BTLA-mediated bait and switch strategy permits Listeria expansion in CD8?(+) DCs to promote long-term T cell responses. Cell Host Microbe 16:68-80|
|Li, Feng; Cowley, Dale O; Banner, Debra et al. (2014) Efficient genetic manipulation of the NOD-Rag1-/-IL2RgammaC-null mouse by combining in vitro fertilization and CRISPR/Cas9 technology. Sci Rep 4:5290|
|Cheng, Liang; Du, Xuexiang; Wang, Zheng et al. (2014) Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses. J Hepatol 61:1297-303|
|Yang, Dan; Liu, Longchao; Zhu, Danming et al. (2014) A mouse model for HBV immunotolerance and immunotherapy. Cell Mol Immunol 11:71-8|